The effects of resveratrol on lipid profiles and liver enzymes in patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials.
Lipid profiles
Liver enzymes
Meta-analysis
Metabolic syndrome
Resveratrol
Journal
Lipids in health and disease
ISSN: 1476-511X
Titre abrégé: Lipids Health Dis
Pays: England
ID NLM: 101147696
Informations de publication
Date de publication:
17 Feb 2020
17 Feb 2020
Historique:
received:
01
04
2019
accepted:
24
01
2020
entrez:
19
2
2020
pubmed:
19
2
2020
medline:
24
11
2020
Statut:
epublish
Résumé
There are current trials investigating the effect of resveratrol supplementation on lipid profiles and liver enzymes among patients with metabolic syndrome (MetS) and related disorders; however, their findings are controversial. This systematic review and meta-analysis were aimed to determine the effects of resveratrol supplementation on lipid profiles and liver enzymes among patients with MetS and related disorders. We performed a comprehensive search of the following online databases up to November 2018: Cochrane Library, PubMed, Embase, and Web of Science. The relevant articles were assessed for quality of studies using the Cochrane risk of bias tool. Out of 2459 citations, 31 articles were appropriate for including to the current meta-analysis. The pooled results indicated that resveratrol use significantly decreased total cholesterol [weighted mean difference (WMD) = - 7.65 mg/dL; 95% CI, - 12.93, - 2.37; P < 0.01; I This meta-analysis demonstrated that resveratrol supplementation among patients with MetS and related disorders significantly reduced total cholesterol and increased GGT concentrations, but did not affect triglycerides, LDL-, HDL-cholesterol, ALT, and AST concentrations. This data suggests that resveratrol may have a potential cardio-protective effect in patients with MetS and related disorders.
Sections du résumé
BACKGROUND
BACKGROUND
There are current trials investigating the effect of resveratrol supplementation on lipid profiles and liver enzymes among patients with metabolic syndrome (MetS) and related disorders; however, their findings are controversial. This systematic review and meta-analysis were aimed to determine the effects of resveratrol supplementation on lipid profiles and liver enzymes among patients with MetS and related disorders.
METHODS
METHODS
We performed a comprehensive search of the following online databases up to November 2018: Cochrane Library, PubMed, Embase, and Web of Science. The relevant articles were assessed for quality of studies using the Cochrane risk of bias tool.
RESULTS
RESULTS
Out of 2459 citations, 31 articles were appropriate for including to the current meta-analysis. The pooled results indicated that resveratrol use significantly decreased total cholesterol [weighted mean difference (WMD) = - 7.65 mg/dL; 95% CI, - 12.93, - 2.37; P < 0.01; I
CONCLUSIONS
CONCLUSIONS
This meta-analysis demonstrated that resveratrol supplementation among patients with MetS and related disorders significantly reduced total cholesterol and increased GGT concentrations, but did not affect triglycerides, LDL-, HDL-cholesterol, ALT, and AST concentrations. This data suggests that resveratrol may have a potential cardio-protective effect in patients with MetS and related disorders.
Identifiants
pubmed: 32066446
doi: 10.1186/s12944-020-1198-x
pii: 10.1186/s12944-020-1198-x
pmc: PMC7026982
doi:
Substances chimiques
Triglycerides
0
Cholesterol
97C5T2UQ7J
Resveratrol
Q369O8926L
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
25Subventions
Organisme : Shiraz University of Medical Sciences
ID : 97105
Références
J Am Coll Cardiol. 2018 Jul 3;72(1):96-118
pubmed: 29957236
Scand J Gastroenterol. 2016;51(4):456-64
pubmed: 26784973
Crit Rev Food Sci Nutr. 2020;60(3):375-390
pubmed: 30421960
Nutr Rev. 2013 Dec;71(12):822-35
pubmed: 24111838
Food Funct. 2018 Dec 13;9(12):6116-6128
pubmed: 30426122
Cell Metab. 2011 Nov 2;14(5):612-22
pubmed: 22055504
Arterioscler Thromb Vasc Biol. 2009 Aug;29(8):1164-71
pubmed: 19478208
Nutrition. 2019 Feb;58:7-10
pubmed: 30278430
Wiad Lek. 2016;69(3 pt 2):475-479
pubmed: 27717928
ISRN Endocrinol. 2014 Feb 20;2014:816307
pubmed: 24701359
Obesity (Silver Spring). 2016 Jul;24(7):1454-63
pubmed: 27221771
Dig Liver Dis. 2015 Mar;47(3):226-32
pubmed: 25577300
Dig Dis Sci. 2012 Feb;57(2):528-34
pubmed: 22183820
Nutr Res. 2018 Jun;54:40-51
pubmed: 29914666
World J Gastroenterol. 2014 Jun 21;20(23):7366-80
pubmed: 24966607
Ther Clin Risk Manag. 2016 Feb 23;12:281-6
pubmed: 26966368
Hepatology. 2007 Oct;46(4):1081-90
pubmed: 17654743
Histochem Cell Biol. 2011 Oct;136(4):475-89
pubmed: 21818579
Nutrition. 2013 Jan;29(1):178-83
pubmed: 23153742
Eur J Clin Nutr. 2016 Jan;70(1):10-6
pubmed: 26059745
Afr J Tradit Complement Altern Med. 2013 Nov 02;11(1):209-12
pubmed: 24653579
Circulation. 1997 Jan 7;95(1):69-75
pubmed: 8994419
Arch Intern Med. 2001 Dec 10-24;161(22):2685-92
pubmed: 11732933
Int J Cardiol. 2015;189:47-55
pubmed: 25885871
Int J Sport Nutr Exerc Metab. 2014 Feb;24(1):2-13
pubmed: 23918588
Diabetes Obes Metab. 2018 Jul;20(7):1793-1797
pubmed: 29484808
Lipids Health Dis. 2018 Oct 9;17(1):230
pubmed: 30296936
J Clin Endocrinol Metab. 2017 May 1;102(5):1642-1651
pubmed: 28182820
Nat Rev Endocrinol. 2017 May;13(5):278-288
pubmed: 28133369
Nutr Res. 2011 Nov;31(11):842-7
pubmed: 22118755
Adipocyte. 2018;7(3):190-196
pubmed: 29786471
Food Funct. 2018 Jul 17;9(7):3845-3852
pubmed: 29951651
Acta Diabetol. 2018 Apr;55(4):341-353
pubmed: 29357033
Am J Clin Nutr. 2016 Jul;104(1):215-27
pubmed: 27194304
Cardiovasc Diagn Ther. 2017 Apr;7(Suppl 1):S21-S31
pubmed: 28529919
Oxid Med Cell Longev. 2018 Mar 18;2018:4147320
pubmed: 29743980
Adv Pharm Bull. 2018 Jun;8(2):307-317
pubmed: 30023333
PLoS One. 2016 Aug 25;11(8):e0161792
pubmed: 27560482
Prim Care. 2013 Mar;40(1):195-211
pubmed: 23402469
Diabetes. 2013 Apr;62(4):1186-95
pubmed: 23193181
Arch Med Sci. 2017 Aug;13(5):965-1005
pubmed: 28883839
J Neurosci. 2014 Jun 4;34(23):7862-70
pubmed: 24899709
Phytother Res. 2017 Jan;31(1):108-114
pubmed: 27807887
Mol Nutr Food Res. 2015 Jan;59(1):147-59
pubmed: 25138371
J Intern Med. 2018 Apr;283(4):356-370
pubmed: 29280273
Nutr Res. 2012 Jul;32(7):537-41
pubmed: 22901562
Nutr Res. 2014 Oct;34(10):837-43
pubmed: 25311610
Evid Based Complement Alternat Med. 2013;2013:851267
pubmed: 24073011
Metab Syndr Relat Disord. 2014 Dec;12(10):497-501
pubmed: 25137036
Br J Haematol. 2007 Nov;139(3):475-85
pubmed: 17868048
Int Heart J. 2017 Aug 3;58(4):577-583
pubmed: 28701674
Arch Med Sci. 2018 Mar;14(2):422-441
pubmed: 29593818
Clin Gastroenterol Hepatol. 2014 Dec;12(12):2092-103.e1-6
pubmed: 24582567
Nutr Metab Cardiovasc Dis. 2007 May;17(4):247-56
pubmed: 17134953
Hepatobiliary Pancreat Dis Int. 2018 Feb;17(1):45-48
pubmed: 29428103
Clin Ter. 2017 Jul-Aug;168(4):e240-e247
pubmed: 28703838
PLoS One. 2015 Mar 19;10(3):e0118393
pubmed: 25790328
Br J Nutr. 2015 Sep 14;114(5):796-803
pubmed: 26234526
Nutrition. 2016 Nov-Dec;32(11-12):1179-92
pubmed: 27324061
Mol Metab. 2018 Jun;12:39-47
pubmed: 29706321
Gut. 2011 Jun;60(6):829-36
pubmed: 21339204